2009•OncoTargets and TherapyOpen access

Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma

Robert Dreicer

Abstract

Advances in the understanding of the biology of renal cell carcinoma have led to recent approval of several new agents including drugs that target vascular endothelial growth factor. Sunitinib is an oral tyrosine kinase inhibitor which interferes with multiple intracellular tumorogenic pathways, and has demonstrated impressive antitumor activity in phase II and subsequently improvement in progression free survival in phase III renal cancer trials. We review the unique side effects of sunitinib therapy with emphasis on establishing effective patient education for anticipation and early management of therapy-related side effects.

Open-access reader

About this research paper

What this paper is about

Why it matters

OpenAlex reports 54 citations for this work. Citation counts describe recorded attention and do not establish research quality.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Key concepts: Sunitinib, Renal cell carcinoma, Medicine, Tyrosine-kinase inhibitor, Kidney cancer, Side effect (computer science), Tyrosine kinase, Anticipation (artificial intelligence)